Research

Plugging Cell Biology Into a Genomic World

(This blog was originally posted on January 15, 2014 on the American Association for Cancer Research website)

Personalized oncology epitomizes the concept of interdisciplinary research where pathologists, bioinformaticians, oncologists, and biologists work together to identify and ultimately target drivers of cancer. We gather at tables to collaborate across disciplines and try to speak the same language with the goals of advancing knowledge and helping patients. As a cancer cell biologist at the Winship Cancer Institute, I have been privileged to be a part of these conversations and to contribute to our efforts to understand tumor biology.

When most researchers talk about personalized (or precision) oncology, genomics is usually an important part of the conversation. Genomic technologies can yield tremendous amounts of information in a relatively unbiased and high-throughput manner. Cell biology, on the other hand, which has interested me for over 15 years, provides a powerful and focused approach to probe the behavior and function of cells, organelles, and proteins. Tremendous leaps have been made over the last two decades that have enhanced our ability to “see” biology due to the advent of technologies such as genetically encoded fluorescent proteins and new imaging modalities. In fact, the Nobel Prize has been awarded twice in the last decade to imaging-based technologies, most recently this past October to the inventors of super-resolution imaging.

Despite these differing approaches, cell biology and genomics are not mutually exclusive; cell (and molecular) biology data are routinely combined with genomic data as a means to validate results. But can cell biology and genomics be more than validation partners? Could a marriage between the focused spatial and temporal power of cell biology with the throughput of genomics create a “best of both worlds” scenario to enhance personalization of cancer treatment?

Watch Dr. Marcus’ TEDx Peachtree talk, “Every Cancer Is Personal.”

As we move into a world of single-cell genomics, we are beginning to unravel the importance of obtaining information from one cell, and consequently yielding tremendous insight into tumor biology, especially tumor heterogeneity and rare cell types. Several strong lines of evidence now suggest that it may be rare cell types, such as cancer stem cells, that are required for initiation and progression of cancer. The ability to develop new methods that can precisely select these rare cell types, perhaps even while the cells are alive using cellular imaging-based approaches, would allow these rare genomes to be extracted. Perhaps, down the road, approaches rooted in cell biology may help provide more temporal -omics where researchers can monitor changes in the transcriptome of single cells or groups of cells over time to understand single tumor cell evolution during initiation, progression, and treatment.

It is not that cell biology is so unique; rather, it is the concept of marrying two research approaches to create a scientific synergy. The advances that are made through interdisciplinary research in the laboratories will not only provide new insight into the biology of cancer but can ultimately impact patients through personalized oncology. The late Steve Jobs said, “Creativity is just about connecting things.” We need to continue to connect things in the lab to create new opportunities in the clinic.

About Dr. Marcus


Adam Marcus, PhDAdam Marcus received his PhD in cell biology from Penn State University in 2002 and went on to do a post-doctoral fellowship in cancer pharmacology at Emory University. Dr. Marcus is an Associate Professor at Emory University School of Medicine and has developed his own laboratory at Winship Cancer Institute, which focuses on cell biology and pharmacology in lung and breast cancer. His laboratory studies how cancer cells invade and metastasize using a combination of molecular and imaging-based approaches. Marcus has been a member of the American Association for Cancer Research since 2003. You can follow him on Twitter at  @NotMadScientist.

Related Resources

Every Cancer Is Personal

Why Winship?

Winship Cancer Institute of Emory University“For every question that we answer or seek to answer, new questions arise.”

Winship’s executive director, Wally Curran , MD, said that in answer to an interview question about Winship, and I think it provides insight on the incremental way that progress is made against cancer.

It also helps describe the dedication of cancer doctors and researchers who are willing to keep pursuing answers to this vastly complex puzzle.

The communications team at Winship has been asking another type of question lately: “Why Winship?” The answers we got are now the basis of a website, social media and poster campaign highlighting stories that show how our doctors, researchers and healthcare staff make discoveries and translate the latest breakthroughs in cancer research into better treatments for patients.

The stories are told through the words and thoughts of people who have been treated at Winship, and through the Winship staff who work toward finding ever-better ways to defeat cancer.

Our first round of “Why Winship?” videos, now on our website, features a group of Winship physicians who represent the comprehensive spectrum of patient care we are able to offer, from the latest drug and radiation therapies, to innovative surgical techniques. Here is a sampling of their thoughts on what makes Winship a unique place for them.

WALTER J. CURRAN, JR., MD
WINSHIP EXECUTIVE DIRECTOR
“Winship is about depth and breadth. It’s the depth and breadth of our team that approaches a cancer problem. For example, in lung cancer, we have depth and breadth in the surgical, pulmonary, oncology, scientific, and epidemiologic teams which confront the leading cancer killer. Without the depth and breadth, we could not make the progress for a given patient and we also could not make the progress for a given problem as complex as lung cancer.”

FADLO R. KHURI, MD
WINSHIP DEPUTY DIRECTOR
“I think there is a spirit of humility and genuine discovery that suffuses the place. People want to know not just why, but why didn’t a treatment work, why didn’t a patient benefit, and go back to understand from every specific patient encounter how we can do better and more importantly how we can help them to do better.”

KAREN GODETTE, MD
WINSHIP RADIATION ONCOLOGIST
“With that team effort, [you’re] getting the best technology, multi-modality therapy with what we call translational research and the up-to-date protocols and everything in one place. Rather than having to hunt around to get the best in each thing you have it right here. An example is our sarcoma conference. There’s a thoracic surgeon, a radiation oncologist, a medical oncologist, everyone is right there at the same time talking about the patient…. you have the best of everything right there.”

PETER ROSSI, MD
Winship Radiation Oncologist
“I know that I am going to be supported to go in the direction I think is most cutting edge that is the best for my patients… You have to have an administration that has a long-term vision of that. You don’t see that commonly and we have that at Winship Cancer Institute.”

VIRAJ MASTER, MD, PhD
Winship Urologist
“What gets me really excited about working at Winship is I have the ability to have incredible collaborative efforts that take place every day, and I particularly point out my colleagues in surgery, be it thoracic surgery, vascular surgery, surgical oncology. We work well together because we truly believe that the sum is greater than the individual. It allows us to do operations that I only dreamed of doing when I was in training, and we do it better here at Winship than anywhere else.”

About Catherine Williams

catherine-williams-2014As Senior Communications Manager for Winship Cancer Institute of Emory University, Catherine Williams creates print, video and electronic communications materials and serves as a media relations contact for consumer health, news and science media.

Catherine came to Winship after 30 years as a television producer in New York, Washington and Atlanta, producing news, magazine and documentary programming. She has won awards for special reports covering health/science, public affairs and entertainment. She says news was exciting but nothing compares to the satisfaction of working with the dedicated and inspiring staff of Winship.

Robotic Surgery Allows for Minimally Invasive Treatment of Colon and Rectal Cancers

Robotic Surgery for Colorectal CancersColon and rectal cancer affects 140,000 Americans each year and is the second leading cause of cancer-related death in the United States. For most patients, surgery is recommended at some point in their care as it is the only curative treatment, and tremendous advances in surgical technique have been achieved during the past 20 years. Most notable has been the dramatic increase in minimally invasive surgical techniques, including laparoscopic surgery, robotic surgery, and transanal endoscopic microsurgery. The advantages of minimally invasive surgery for patients include shorter hospital stays, less postoperative pain, more positive cosmetic outcomes, and shorter recovery time at home, allowing earlier return to work and normal activities. Importantly, minimally invasive techniques allow patients to resume their other postoperative treatments (i.e., chemotherapy) sooner, with less disruption in their overall care plan.

The addition of robotic surgery to the minimally invasive armamentarium has been a “game-changer,” since it means that minimally invasive approaches can now be used for even the most difficult colon and rectal cancers. The robotic approach can facilitate visualization in difficult locations such as the deep pelvis, allowing for more precise dissections and less blood loss. This can translate to better patient outcomes in many situations, especially in allowing for “sphincter-preserving surgery”—avoiding the need for permanent “bags” or colostomies.

Emory Johns Creek Hospital (EJCH), with the leadership of Dr. Seth Rosen, has developed a nationally recognized Robotic Colorectal Surgery program, and strives to provide the most up-to-date, multi-disciplinary care for patients with Colon and Rectal Cancer. With advanced approaches to pain management and post-operative protocols that enhance recovery times, patients are discharged home earlier, and have fewer post-operative complications. Multi-institutional studies confirm that patients who have access to a board certified colorectal surgeon with a high volume of robotic surgery experience fewer short-term complications and improved long-term cancer survival. At EJCH, patients with Colon and Rectal Cancer are managed by a team of experts including medical oncologists, radiation oncologists, nutritionists, specialty nurses, physical therapists, and pharmacists.

Dr. Seth Rosen’s experience and data has resulted in him being recognized as a “center of excellence” in robotic colon and rectal surgery. He has presented data at numerous meetings, and instructed surgeons from all over the United States in techniques of robotic colorectal surgery.

 

Every Cancer is Personal

As a cancer researcher, I’ve delivered plenty of lectures, but nothing compares with a talk I gave in October to an audience of 500 strangers. My TEDx address focused on how the treatment and diagnosis of cancer is becoming more personal. Scientists across the world are going all-in on determining the driving genetic changes for each individual cancer to better personalize treatment for each patient. In my talk, I tried to emphasize where hope lives for cancer treatment in the next 5-10 years based upon this approach and how my laboratory at the Winship Cancer Institute is contributing to this effort.

Although I went into the day looking to impact others, I never expected the event to have such an impact on me. There were a dozen speakers that day with talks ranging from robotics and mathematics to tap dancing and beatboxing. The day of mass-education concluded with an impromptu parade throughout the Buckhead theatre. Hundreds of adults dressed in business attire lined up and were parading, dancing, singing and beatboxing. People that barely knew each other enjoyed interacting and sharing ideas throughout the day with the primary purpose of learning. I was clearly not in the familiar lecture halls and laboratories at the Emory School of Medicine, but I felt right at home and was happy to share my passion and knowledge about a subject that impacts so many of us.

About Dr. Marcus

Adam Marcus, PhDAdam Marcus received his PhD in cell biology from Penn State University in 2002 and went on to do a post-doctoral fellowship in cancer pharmacology at Emory University. Dr. Marcus is an Associate Professor at Emory University School of Medicine and has developed his own laboratory which focuses on cell biology and pharmacology in lung and breast cancer. Dr. Marcus’ laboratory studies how cancer cells invade and metastasize using a combination of molecular and imaging-based approaches. For more information about Dr. Marcus and his outreach and research efforts, please use the related resources links below. You can also follow Dr. Marcus on Twitter at @NotMadScientist.

Related Resources

Lung Cancer Progress Made, But We’re Not There Yet

Lung Cancer (This blog was originally posted on September 29, 2014 on the American Association for Cancer Research website)

Luther Terry, the ninth Surgeon General of the United States, released his now seminal Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States on Jan. 11, 1964. The report, assembled by a brave and committed panel of independent physicians and scientists, definitively concluded that lung cancer and chronic bronchitis are causally related to cigarette smoking.

Fifty years later, genomic discovery and the rapidly accelerating fields of epigenetics, proteomics, metabolomics, and drug discovery have presented an armada of new options for patients with lung cancer. Computed tomography (CT) screening of high-risk individuals, particularly smokers, helps detect the disease in its early, more-curable stages more than 80 percent of the time. Breakthroughs in cancer immunology have led to the accelerated development of PD-1 and PD-L1 inhibitors, demonstrating remarkable and durable benefits in early clinical trials of lung cancer patients with advanced disease. But in 2014, five-year survival remains under 20 percent for patients diagnosed with lung cancer and more than 1.5 million people worldwide will die of lung cancer. Moreover, smoking rates, while down to 19 percent in the U.S., remain well over 30 percent in much of the rest of the world.

Despite the armada of new targeted medicines, cure remains elusive for the vast majority of patients diagnosed with this dreaded illness, and a significant number of never-smokers seem to contract this disease without any known risk factors. So why are we optimistic that major progress made in science can meaningfully impact lung cancer?

2014 has seen major strides in lung cancer research and treatment. Smoking cessation efforts have accelerated with the Food and Drug Administration’s (FDA) increased abilities to enforce regulations on tobacco products. Our understanding of lung cancer biology grows exponentially by the day. A number of exciting trials have been launched this year to test targeted agents in the adjuvant, postoperative setting, as well for therapy of patients with advanced stage disease. Exciting clinical trials have led to the approval of second- and third-generation agents targeting oncogene-driven tumors. A major initiative has been launched to target RAS, the most frequently mutated oncogene in all cancer, and a major driver of outcomes in lung cancer.

Substantial progress has been achieved this year in targeted therapy, stereotactic radiation, and immunotherapy of lung cancer. Collaborative work demonstrated that patients with metastatic lung cancer who were treated successfully by targeting their oncogenic drivers do better than individuals who were treated with standard approaches across several centers of excellence, and that work needs to be successfully translated in the community for all patients with lung cancer in the coming years. While emergence of resistance, triggered through enhanced survival signaling circuits, is inevitable in these highly complex tumors, our understanding of these escape circuits is accelerating rapidly. We are learning to combine improved imaging methods with superior technology to detect circulating tumor cells in order to identify and treat patients with disease earlier than ever before.

However, we have yet to show we can successfully intervene in lung carcinogenesis. In a large trial that we performed in the ECOG-ACRIN Cancer Research Group, we found that natural compounds are incapable of reversing the damage caused by ongoing tobacco smoke. We must ally smoking cessation and early detection, and enhance our understanding of the cause of disease in never-smokers. We need to develop potent but tolerable compounds that can reverse premalignant lesions in former smokers.

While the 2009 Tobacco Control Act has enhanced the FDA’s ability to regulate tobacco products in some key areas, such as marketing to minors, major obstacles regarding the regulation of cigars, water pipes, menthol, and particularly e-cigarettes have limited the FDA’s ability to more effectively regulate the menace of Big Tobacco. Indeed, the booming electronic cigarettes industry threatens to enable a whole new generation of smokers. Unless we act decisively to carefully regulate the use of e-cigarettes, the steady progress made in lung cancer research and therapy over the past few decades could be eroded. It is only when we effectively reduce smoking by enforcing the FDA’s control of all products and implementing tobacco control programs with real teeth while simultaneously unraveling and preventing the causes of lung cancer in never-smokers that we will truly start to make an impact, fulfilling Surgeon General Terry’s and, most importantly, our patients’ goals to make lung cancer a disease of prior generations, and a scourge no more.

About Dr. Khuri

Fadlo Khuri, MDFadlo R. Khuri, MD, deputy director of the Winship Cancer Institute of Emory University and Professor and Chairman of the Department of Hematology & Medical Oncology, Emory University School of Medicine, is a leading researcher and physician in the treatment of lung and head and neck cancers. He is Editor-in-Chief of the American Cancer Society’s peer-reviewed journal, Cancer.

Dr. Khuri’s contributions have been recognized by a number of national awards, including the prestigious 2013 Richard and Hinda Rosenthal Memorial Award, given to an outstanding cancer researcher by the American Association for Cancer Research.

An accomplished molecular oncologist and translational thought leader, Dr. Khuri has conducted seminal research on oncolytic viral therapy, developed molecular-targeted therapeutic approaches for lung and head and neck tumors combining signal transduction inhibitors with chemotherapy, and has led major chemoprevention efforts in lung and head and neck cancers. Dr. Khuri’s clinical interests include thoracic and head and neck oncology. His research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco related cancers. His laboratory is investigating the mechanism of action of signal transduction inhibitors in lung and aerodigestive track cancers.

Latest in Breast Cancer Research

According to the National Breast Cancer Foundation, 10%-20% of diagnosed breast cancers are determined to be triple negative breast cancer. It tends to primarily affect younger, premenopausal women and is more aggressive than other types of breast cancer. Studies show that African-American and Hispanic women are more likely to be diagnosed with triple negative breast cancer than white women. Triple negative breast cancers don’t have the three types of receptors that most commonly fuel breast cancer growth — estrogen, progesterone and the HER2 gene — so they don’t respond to hormonal therapies and treatments that target those receptors. Chemotherapy is typically used for treatment, but there is an urgent need to find more precise therapies.

LaTonia Taliaferro-Smith, PhD, is one of the Winship Cancer Institute of Emory University’s scientists who have taken up the challenge to develop more targeted therapies. In her lab research, Taliaferro-Smith searches for alternative targets in the triple negative breast cancer cell. She works closely with Winship physician-researchers toward the goal of developing drugs that will benefit patients with this disease.

“I’m very hopeful about the research we’re doing here and what Winship is offering to triple negative breast cancer patients,” says Taliaferro-Smith. “Oftentimes when patients hear a triple negative diagnosis, they think there are no options and ultimately their endpoint is death. But we’re very encouraged here at Winship because we do have active research that is trying to find alternative therapies for these particular patients, so we can let them know that you will have treatment options available hopefully in the near future.”

Check out the video below as Dr. Taliaferro- Smith discusses the continuous work research teams at Winship are doing to develop more precise treatment therapies for triple negative breast cancer:

Related Resources

Learn more about breast cancer care at Winship at Emory. October is Breast Cancer Awareness Month and our breast care teams want you to know that early detection is key to survival. Have questions about the role of screening in early breast cancer detection? Join us for a live web chat with a breast imaging expert on October 21, 204.

Winship’s Win the Fight 5K Exceeds Fundraising Goal to Help Battle Cancer

Winship Win the Fight 5K RecapThis past weekend,  Winship Cancer Institute of Emory University raised a record amount of money towards cancer research in Georgia. Fundraising support, through the 4th annual Winship Win the Fight 5K, which was held on Saturday, September 27, 2014, surpassed its half-million dollar goal and brought in more than $582,000. Over three thousand runners and walkers gathered Saturday morning to participate in the event that started and ended on the Emory campus and wound its way through the surrounding Druid Hills-area.

“We are so grateful to all the supporters who joined us at this year’s Winship 5K,” says Walter J. Curran, Jr., MD, executive director of Winship. “The money raised will support more than a dozen cancer research projects at Winship and will lead us to more and more success stories in our fight against cancer.”

The Winship Win the Fight 5K is a unique event because it allows participants to select the specific area(s) of cancer research they want their tax-deductible donations to benefit. Donations are still being accepted until November 14, 2014. For more information, visit the Winship Win the Fight 5K website.

And make sure to mark your calendars for the 5th annual Winship Win the Fight 5K, which will be held on Saturday, October 3, 2015.

Winship Win the Fight 5K

Winship Fight 5KThe Winship Win the Fight 5K is this Saturday, September 27, 2014 and already a HALF A MILLION DOLLARS has been raised towards cancer research at Winship Cancer Institute of Emory University.

There’s still time to be a part of this special event! Today is the last day to register online for Saturday’s event. If you cannot be present to run or walk this weekend, register as a “Sleep-In Warrior” to support cancer research from wherever you will be this weekend.

For more information, or to register, visit the Winship Win the Fight 5K website. Also, check out this inspiring video below featuring WSB-TV’s Mark Winne’s wife, Kate, a cancer survivor and Winship patient. Mark and Kate’s story not only shows the crucial role cancer research plays in the continuous fight for a world without cancer, but also the hope it beings to patients and families, here and now.

Related Resources:

Cancer Researchers, Patients Support Winship 5K Side-by-Side
Why I Run: To Raise Awareness & Funding For My Dad’s Cancer
Running to Carry Forth a Father’s Passion to Make a Difference…

What the Inside of an Operating Room is Like During a Life-Saving Procedure

Operating RoomIt’s 7 a.m. and the surgical staff at Emory University Hospital is prepping a patient for a potentially life-saving procedure. As a surgical oncologist at the Winship Cancer Institute of Emory University, I am leading one of the two groups of specialists working together to remove a type of stomach tumor known as a gastrointestinal stromal tumor (GIST). This is a rare tumor with approximately 10,000 new cases diagnosed in the Unites States every year. If left untouched, the tumor could enlarge or metastasize, requiring more radical treatment.

Stomach tumors are usually removed using one of two common techniques: endoscopy, in which doctors enter through the patient’s mouth using a flexible tube outfitted with a miniature camera and lasso-like device; or surgery, in which surgeons use minimally-invasive laparoscopic techniques to insert tiny surgical instruments through small incisions in the abdomen.

For this particular case, Dr. Field Willingham, Director of Endoscopy in the Emory Division of Digestive Diseases, and I are performing a groundbreaking hybrid procedure using both laparoscopy and endoscopy simultaneously, which allows us to reach tumors located in difficult areas of the stomach. In many cases, this procedure leads to the complete and safe removal of the tumor with fewer complications and/or long-term problems for the patient.

During the actual procedure, I begin by using laparoscopic tools to push the tumor from the outer side of the stomach so the more easily Dr. Willingham can grab the bulge from inside the stomach using an endoscopic cutting loop. I am able to push the tumor into the lumen of the stomach and Dr. Willingham successfully removes the tumor using a surgical snare technique. Next, Dr. Willingham pushes the area of the stomach where we removed the tumor from towards me. That allows me to hold the wall of the stomach and cut away any remaining tumor cells that may have been left behind.

By 10 a.m., the keyhole-sized incisions in the patient’s abdomen are being stitched closed. This particular operation is a complete success! We have safely removed the malignancy, leaving the patient’s lifestyle and ability to eat intact.

Emory was one of the first medical centers in the country to use this hybrid technique. We work closely with our colleagues in Gastroenterology to remove these complex tumors without requiring the patient to go through invasive surgery or complete organ removal.

While developing and performing innovative procedures like this is made easier by advanced technology and surgical techniques, a key to overall success is the multi-disciplinary team approach. While it helps that Dr. Willingham and I are friends outside of the operating room, it is very important as colleagues that we communicate and collaborate with one another, especially during complex cases such as this GIST surgery. Leaning on each other’s area of expertise, while sharing the same goal of doing what is best for our patient, leads to successful outcomes only achieved by working together.

See Dr. Maithel and Dr. Willingham performing this innovative procedure in the video below!

About Dr. Maithel

Shishir Maithel, MDShishir K. Maithel, MD, FACS, Assistant Professor of Surgery, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, is a surgical oncologist at Winship Cancer Institute. Dr. Maithel specializes in treating gastrointestinal cancers, cancer of the liver, bile duct and pancreas, and retroperitoneal sarcoma. Dr. Maithel joined Emory in 2009 from Memorial Sloan-Kettering Cancer Center in New York where he completed his fellowship in both surgical oncology and hepatopancreatobiliary surgery. He completed his residency and internship at Beth Israel Deaconess Medical Center at Harvard Medical School. Dr. Maithel earned his Medical Degree at the University of Chicago, Pritzker School of Medicine, graduating Alpha Omega Alpha.

Bringing the Invisible Into Georgia Classrooms

Microscope view of cellsOn many university campuses there is a dark room that has no windows and the walls are painted black. People wearing white lab coats enter and rest their eyes on top of what I think to be one the most magnificent instruments in a science laboratory, the microscope. These microscopes, which are no bigger than a desk but can cost more than a house, rest gently on a cushion of air and serve the purpose of making the invisible world, visible.

I was hooked the first time I peered into one of these microscopes. All of a sudden this entirely new and previously invisible world moved into focus right in front of me. Tiny creatures that I had apparently been living with, were visible for the first time. I eventually turned my obsession with the microscopic world into a career. I am a scientist at a major medical school and my laboratory’s research is to study how cancer cells work, with the goal of creating new cancer treatments. My team and I have killed cancer cells with new medicines, burst them open, blasted them with radiation, and blocked them from spreading. We do this with the hope that our research will lead to new cancer treatments, make older treatments better, or help diagnose cancer.

Now I have been trying to bring this fascination for microscopes and cells into the classrooms of children around the state of Georgia with my program Students for Science. Through this program I have traveled to over 200 K-12 classrooms and seen over 2000 children in about 35 schools. I usually travel with three microscopes, computers, and cameras, and I bring with me other Winship Cancer Institute scientists, scientists in training from our graduate school, and Emory University undergraduates. Our goal is to inspire critical thinking in K-12 schools by providing them with hands-on, thought-provoking science activities that use the microscope. We have worked with the school students to see their own cheek cells, pond water, microorganisms in dirt, moss, bugs, and plants. I also show them real science movies taken on the microscopes at Emory to promote critical thinking and age-appropriate discussion about science and cancer.

I think that all of us participating in the program believe in its potential long-term benefit of growing the next generation of Georgia scientists. One of our major goals is to have the school students see real scientists to make the possibility of becoming a scientist more tangible. In addition, for me personally it is the excitement and thrill that the children show the first time they peer down the microscope and observe cells zipping across the microscope slide. Some children show fascination, others bewilderment, and some just scream out loud. These reactions are priceless and motivate me to continue to grow the program, see more classrooms, and help educate our youngest scientists.

About Dr. Marcus
Dr. Adam MarcusAdam Marcus received his PhD in cell biology from Penn State University in 2002 and went on to do a post-doctoral fellowship in cancer pharmacology at Emory University. Dr. Marcus is an Associate Professor at Emory University School of Medicine and has developed his own laboratory which focuses on cell biology and pharmacology in lung and breast cancer. Dr. Marcus’ laboratory studies how cancer cells invade and metastasize using a combination of molecular and imaging-based approaches. For more information about Dr. Marcus and his outreach and research efforts, please use the related resources links below. You can also follow Dr. Marcus on Twitter at @NotMadScientist.

 

 

Related Resources: